Universal Ibogaine EBIT

Universal Ibogaine (IBOGF) currently reports a EBIT of $-720K as of April 2025. That compares with $-810K in the prior-year period — up 11.8% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore Universal Ibogaine's EBIT history and peer comparisons.

Universal Ibogaine's EBIT increased from $-810K to $-720K — a 11.8% year-over-year increase (period ending April 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Universal Ibogaine's EBIT of $-720K is lower than the Healthcare sector average of $99B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Universal Ibogaine reported $-720K in EBIT as of April 2025. That compares with $-810K in the prior-year period — up 11.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-720K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for Universal Ibogaine, and consider following IBOGF for alerts when major investors trade the stock.